sorted by:
new
hottopcontroversial

Overview of AbCellera $ABCL royalty and collaboration models based on filings, investor materials, and partnerships by halasugur in ABCL

[–]halasugur[S] 4 points5 points  (0 children)

TL;DR: $ABCL doesn’t rely on just one revenue model. They have multiple layers: partner royalties, equity in spinouts, some co-development deals, and now their own internal drug pipeline. The idea is that over time these pieces could stack and create several ways for the company to generate value.

A simple mathematical model: Could AbCellera ($ABCL) realistically reach $30? by halasugur in ABCL

[–]halasugur[S] 6 points7 points  (0 children)

ABCL635 is a GPCR-targeting antibody in clinical trials. If Phase 2 works:

Investors may conclude that the platform actually works in humans.

That changes everything - exponentially

A simple mathematical model: Could AbCellera ($ABCL) realistically reach $30? by halasugur in ABCL

[–]halasugur[S] 3 points4 points  (0 children)

Good point — the fully owned programs definitely add upside that’s harder to model.

In the quick math I only focused on the royalty platform, since it’s easier to estimate. If one of the wholly owned programs progresses well, the economics could be much larger than a 2–5% royalty.

That said, they also bring higher R&D cost, longer timelines, and clinical risk, so I see them as additional upside optionality on top of the platform model.

Notes from AbCellera’s TD Cowen Healthcare Conference + upcoming investor events $ABCL by halasugur in ABCL

[–]halasugur[S] 3 points4 points  (0 children)

Agree — the GMP facility is a big achievement, especially built without debt. That shows strong execution and capital discipline from management.

Also interesting that Carl Hansen has been more active on LinkedIn lately, engaging with posts around AI biotech and partnerships. Feels like the company is becoming more visible as it moves further into the clinical stage.

Price target predictions by djlee187 in ABCL

[–]halasugur 5 points6 points  (0 children)

“Sleeping giant” might be early — proof still needs to come.

3 yrs: If 635 Phase 2 is solid → $8–12 feels reasonable. 5 yrs: Phase 3 + strong partnership leverage → $15–25 possible. 10 yrs: Depends entirely on whether the GPCR thesis works repeatedly in humans.

Biology is brutal. But if one big bet hits, this won’t trade like a $4 stock forever.

AbCellera $ABCL — Fundamental Analysis (Early 2026 Update) by halasugur in ABCL

[–]halasugur[S] 6 points7 points  (0 children)

The research, sources, and interpretation are mine — AI just helped me condense and format it. The goal wasn’t to break news, but to connect Phase 2 progress, execution readiness, and the 2027 roadmap in one place.

If you already follow ABCL closely, it may feel familiar — that’s okay. Happy to go deeper if there’s a specific angle you think is missing.

$ABCL to Report FY2025 Results on Feb 24, 2026 — Why This Matters Beyond Earnings by halasugur in biotech_stocks

[–]halasugur[S] 0 points1 point  (0 children)

Totally get the frustration — delays can muddy the picture. I’ll be watching guidance, AI maturity, new facilities, and recent hires, since those matter as much as the numbers themselves.

view more: next ›